Review




Structured Review

Mastocytosis Society avapritinib, kit d816v
Avapritinib, Kit D816v, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d816v+kit/kit+d816v/pmc11996035-5-2-4
Average 90 stars, based on 1 article reviews
avapritinib, kit d816v - by Bioz Stars, 2026-10
90/100 stars

Images

Related Articles

other:

Article Title: Systemic Mastocytosis: Current Status and Challenges in 2024.
Article Snippet: Wilson TM, Maric I, Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.

Article Title: Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth
Article Snippet: On the other hand, KIT signaling can enhance MITF expression in mastocytosis, a rare disorder caused by activating KIT mutations, most commonly KIT D816V, leading to excessive mast cell proliferation and accumulation in tissues.

Article Title: Avapritinib for Systemic Mastocytosis
Article Snippet: Avapritinib, kit d816v, systemic mastocytosis (sm), c-findings, midostaurin, indolent sm, advanced sm, aggressive sm (asm), mast cell leukemia (mcl), sm with an associated hematologic neoplasm (sm-ahn)

Article Title: Mastocytosis.
Article Snippet: Mastocytosis is a spectrum of clonal myeloid disorders defined by abnormal growth and accumulation of mast cells in various organ systems.. The disease is divided into cutaneous mastocytosis, systemic mastocytosis (SM) and mast cell sarcoma.. SM is further categorized into several non-advanced and advanced forms.

Mutagenesis:

Article Title: Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications
Article Snippet: .. Furthermore, systemic mastocytosis (SM), a rare condition, is characterized by a KIT D816V mutation in approximately 95% of cases. ..

Article Title: Current and future therapeutics targeting mast cells in disease.
Article Snippet: Mast cells (MCs) are tissue resident immune cells which are best known for their detrimental role in allergy.. Increasing evidence indicates that MCs are also central to the pathogenesis of chronic urticaria.. Abnormal increase in MC burden, in most cases driven by gain-of-function mutations in the receptor KIT, can also lead to mastocytosis, a potentially severe malignant disease.

Variant Assay:

Article Title: Childhood mastocytosis: challenges and potential shortfalls in current disease classification.
Article Snippet: 16 17 The skin is the organ most frequently involved in childhood mastocytosis.. In this article, we present 18 a comprehensive update on recent relevant data in the field of childhood mastocytosis, and critically 19 review the drawbacks of its current classification and skin manifestations.. We hypothesize that two 20 main types of childhood mastocytosis can be recognized, with relevant implications for the outcome, 21 management and understanding of the disease.

Diagnostic Assay:

Article Title: Childhood mastocytosis: challenges and potential shortfalls in current disease classification.
Article Snippet: 16 17 The skin is the organ most frequently involved in childhood mastocytosis.. In this article, we present 18 a comprehensive update on recent relevant data in the field of childhood mastocytosis, and critically 19 review the drawbacks of its current classification and skin manifestations.. We hypothesize that two 20 main types of childhood mastocytosis can be recognized, with relevant implications for the outcome, 21 management and understanding of the disease.



Similar Products

86
Mastocytosis Society p d816v kit p d419del
Correlation between the <t>KIT</t> <t>p.D816V</t> VAF by ASOqPCR and the Flow-SuperRCA. Correlation between the KIT p.D816V VAF by ASOqPCR (A) vs the Flow-SuperRCA (B) assay in paired BM (C) and PB (D) samples from patients with MCAS and mastocytosis distributed according to the diagnostic subtype of both diseases. LOD of the ASOqPCR assay: 0.005% VAF. LOD of the flow SuperRCA assay: 0.001% VAF.
P D816v Kit P D419del, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d816v+kit/activity+d816v+transcriptional/pmc12883851-218-12-61
Average 86 stars, based on 1 article reviews
p d816v kit p d419del - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Mastocytosis Society p d816v kit p d419del n 1
Correlation between the <t>KIT</t> <t>p.D816V</t> VAF by ASOqPCR and the Flow-SuperRCA. Correlation between the KIT p.D816V VAF by ASOqPCR (A) vs the Flow-SuperRCA (B) assay in paired BM (C) and PB (D) samples from patients with MCAS and mastocytosis distributed according to the diagnostic subtype of both diseases. LOD of the ASOqPCR assay: 0.005% VAF. LOD of the flow SuperRCA assay: 0.001% VAF.
P D816v Kit P D419del N 1, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d816v+kit/activity+d816v+transcriptional/pm40811860-64-9-39
Average 86 stars, based on 1 article reviews
p d816v kit p d419del n 1 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

90
Mastocytosis Society kit d816v
Correlation between the <t>KIT</t> <t>p.D816V</t> VAF by ASOqPCR and the Flow-SuperRCA. Correlation between the KIT p.D816V VAF by ASOqPCR (A) vs the Flow-SuperRCA (B) assay in paired BM (C) and PB (D) samples from patients with MCAS and mastocytosis distributed according to the diagnostic subtype of both diseases. LOD of the ASOqPCR assay: 0.005% VAF. LOD of the flow SuperRCA assay: 0.001% VAF.
Kit D816v, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d816v+kit/kit+d816v/pmc12060441-15-23-11
Average 90 stars, based on 1 article reviews
kit d816v - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Mastocytosis Society kit d816v mutation
Correlation between the <t>KIT</t> <t>p.D816V</t> VAF by ASOqPCR and the Flow-SuperRCA. Correlation between the KIT p.D816V VAF by ASOqPCR (A) vs the Flow-SuperRCA (B) assay in paired BM (C) and PB (D) samples from patients with MCAS and mastocytosis distributed according to the diagnostic subtype of both diseases. LOD of the ASOqPCR assay: 0.005% VAF. LOD of the flow SuperRCA assay: 0.001% VAF.
Kit D816v Mutation, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d816v+kit/kit+d816v/pmc12057143-246-12-2
Average 90 stars, based on 1 article reviews
kit d816v mutation - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Mastocytosis Society kit d816v cells
Correlation between the <t>KIT</t> <t>p.D816V</t> VAF by ASOqPCR and the Flow-SuperRCA. Correlation between the KIT p.D816V VAF by ASOqPCR (A) vs the Flow-SuperRCA (B) assay in paired BM (C) and PB (D) samples from patients with MCAS and mastocytosis distributed according to the diagnostic subtype of both diseases. LOD of the ASOqPCR assay: 0.005% VAF. LOD of the flow SuperRCA assay: 0.001% VAF.
Kit D816v Cells, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d816v+kit/kit+d816v/pm40274818-725-13-16
Average 90 stars, based on 1 article reviews
kit d816v cells - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Mastocytosis Society d816v kit variant
Correlation between the <t>KIT</t> <t>p.D816V</t> VAF by ASOqPCR and the Flow-SuperRCA. Correlation between the KIT p.D816V VAF by ASOqPCR (A) vs the Flow-SuperRCA (B) assay in paired BM (C) and PB (D) samples from patients with MCAS and mastocytosis distributed according to the diagnostic subtype of both diseases. LOD of the ASOqPCR assay: 0.005% VAF. LOD of the flow SuperRCA assay: 0.001% VAF.
D816v Kit Variant, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d816v+kit/kit+d816v/pm40243004-15-2-17
Average 90 stars, based on 1 article reviews
d816v kit variant - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Mastocytosis Society avapritinib, kit d816v
Correlation between the <t>KIT</t> <t>p.D816V</t> VAF by ASOqPCR and the Flow-SuperRCA. Correlation between the KIT p.D816V VAF by ASOqPCR (A) vs the Flow-SuperRCA (B) assay in paired BM (C) and PB (D) samples from patients with MCAS and mastocytosis distributed according to the diagnostic subtype of both diseases. LOD of the ASOqPCR assay: 0.005% VAF. LOD of the flow SuperRCA assay: 0.001% VAF.
Avapritinib, Kit D816v, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d816v+kit/kit+d816v/pmc11996035-5-2-4
Average 90 stars, based on 1 article reviews
avapritinib, kit d816v - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Mastocytosis Society kit d816v mutation analysis
Correlation between the <t>KIT</t> <t>p.D816V</t> VAF by ASOqPCR and the Flow-SuperRCA. Correlation between the KIT p.D816V VAF by ASOqPCR (A) vs the Flow-SuperRCA (B) assay in paired BM (C) and PB (D) samples from patients with MCAS and mastocytosis distributed according to the diagnostic subtype of both diseases. LOD of the ASOqPCR assay: 0.005% VAF. LOD of the flow SuperRCA assay: 0.001% VAF.
Kit D816v Mutation Analysis, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d816v+kit/kit+d816v/pm39751701-246-17-23
Average 90 stars, based on 1 article reviews
kit d816v mutation analysis - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Correlation between the KIT p.D816V VAF by ASOqPCR and the Flow-SuperRCA. Correlation between the KIT p.D816V VAF by ASOqPCR (A) vs the Flow-SuperRCA (B) assay in paired BM (C) and PB (D) samples from patients with MCAS and mastocytosis distributed according to the diagnostic subtype of both diseases. LOD of the ASOqPCR assay: 0.005% VAF. LOD of the flow SuperRCA assay: 0.001% VAF.

Journal: Blood

Article Title: Improved diagnostic screening and classification of clonal mast cell diseases by ultrasensitive KIT p.D816V detection ∗

doi: 10.1182/blood.2025029507

Figure Lengend Snippet: Correlation between the KIT p.D816V VAF by ASOqPCR and the Flow-SuperRCA. Correlation between the KIT p.D816V VAF by ASOqPCR (A) vs the Flow-SuperRCA (B) assay in paired BM (C) and PB (D) samples from patients with MCAS and mastocytosis distributed according to the diagnostic subtype of both diseases. LOD of the ASOqPCR assay: 0.005% VAF. LOD of the flow SuperRCA assay: 0.001% VAF.

Article Snippet: A total of 12 patients (4%) displayed KIT mutations other than KIT p.D816V: KIT p.D419del (n = 1), KIT p.K509I (n = 2), KIT p.V532I (n = 2), KIT p.D816H (n = 3), KIT p.D816Y (n = 3), and KIT p.I817T (n = 1); these cases represented 1 of 27 (4%) patients with MMAS and 11 of 220 (5%) patients with mastocytosis.

Techniques: Diagnostic Assay

Diagnostic screening algorithm based on KIT p.D816V testing with the new sensitive Flow-SuperRCA assay for patients with MCAS without skin lesions. Clonality can be demonstrated through detection of an activating KIT mutation in BM and/or PB gDNA with the most sensitive method (Flow-SuperRCA) and/or by demonstrating aberrant CD25, CD2, and/or CD30 expression in BMMCs by flow cytometry immunophenotyping and/or immunohistochemistry.

Journal: Blood

Article Title: Improved diagnostic screening and classification of clonal mast cell diseases by ultrasensitive KIT p.D816V detection ∗

doi: 10.1182/blood.2025029507

Figure Lengend Snippet: Diagnostic screening algorithm based on KIT p.D816V testing with the new sensitive Flow-SuperRCA assay for patients with MCAS without skin lesions. Clonality can be demonstrated through detection of an activating KIT mutation in BM and/or PB gDNA with the most sensitive method (Flow-SuperRCA) and/or by demonstrating aberrant CD25, CD2, and/or CD30 expression in BMMCs by flow cytometry immunophenotyping and/or immunohistochemistry.

Article Snippet: A total of 12 patients (4%) displayed KIT mutations other than KIT p.D816V: KIT p.D419del (n = 1), KIT p.K509I (n = 2), KIT p.V532I (n = 2), KIT p.D816H (n = 3), KIT p.D816Y (n = 3), and KIT p.I817T (n = 1); these cases represented 1 of 27 (4%) patients with MMAS and 11 of 220 (5%) patients with mastocytosis.

Techniques: Diagnostic Assay, Mutagenesis, Expressing, Flow Cytometry, Immunohistochemistry